Victrex plc (LON:VCT) insider Richard Armitage acquired 1,010 shares of the business’s stock in a transaction that occurred on Wednesday, December 5th. The stock was bought at an average cost of GBX 2,318 ($30.29) per share, for a total transaction of £23,411.80 ($30,591.66).

VCT opened at GBX 2,294 ($29.98) on Friday. Victrex plc has a 12 month low of GBX 1,826 ($23.86) and a 12 month high of GBX 2,772 ($36.22).

The firm also recently declared a dividend, which will be paid on Friday, February 22nd. Shareholders of record on Thursday, January 31st will be given a dividend of GBX 128.82 ($1.68) per share. The ex-dividend date is Thursday, January 31st. This is a boost from Victrex’s previous dividend of $13.42. This represents a yield of 5.46%.

VCT has been the topic of several research reports. Morgan Stanley cut shares of Victrex to an “underweight” rating and cut their price objective for the company from GBX 2,500 ($32.67) to GBX 2,300 ($30.05) in a research report on Friday, October 12th. Liberum Capital reaffirmed a “buy” rating on shares of Victrex in a research report on Tuesday, October 16th. UBS Group reaffirmed a “buy” rating and issued a GBX 3,600 ($47.04) price objective (up from GBX 3,300 ($43.12)) on shares of Victrex in a research report on Thursday, October 4th. Peel Hunt reaffirmed an “add” rating on shares of Victrex in a research report on Tuesday. Finally, Barclays reaffirmed an “underweight” rating and issued a GBX 2,420 ($31.62) price objective on shares of Victrex in a research report on Wednesday. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of GBX 2,527.73 ($33.03).

TRADEMARK VIOLATION WARNING: “Richard Armitage Acquires 1,010 Shares of Victrex plc (VCT) Stock” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this report can be viewed at

About Victrex

Victrex plc, through its subsidiaries, manufactures and sells polymers worldwide. It operates through two segments, Victrex Polymer Solutions and Invibio Biomaterial Solutions. The company offers VICTREX PEEK polymer materials; and biomaterial solutions for use in spine, dental, trauma, knee, cardiovascular, and orthopedic applications.

See Also: Catch-Up Contributions

Insider Buying and Selling by Quarter for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with's FREE daily email newsletter.